Concise Drug Review: Pazopanib and Axitinib

• Published in: The oncologist (Dayton, Ohio) Ohio), 2012-08, Vol.17 (8), p.1081-1089
• Main Authors: Geel, Robin M.J.M., Beijnen, Jos H., Schellens, Jan H.M.
• Format: Article
• Language: English
• Subjects: Angiogenesis; Angiogenesis Inhibitors - administration & dosage; Angiogenesis Inhibitors - adverse effects; Angiogenesis Inhibitors - pharmacokinetics; Axitinib; Carcinoma, Renal Cell - drug therapy; Carcinoma, Renal Cell - pathology; Drug profile; Humans; Imidazoles - administration & dosage; Imidazoles - adverse effects; Imidazoles - pharmacokinetics; Indazoles - administration & dosage; Indazoles - adverse effects; Indazoles - pharmacokinetics; Kidney Neoplasms - drug therapy; Kidney Neoplasms - pathology; Meta-Analysis as Topic; New Drug Development and Clinical Pharmacology; Pazopanib; Pyrimidines - administration & dosage; Pyrimidines - adverse effects; Pyrimidines - pharmacokinetics; Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors; Receptors, Vascular Endothelial Growth Factor - therapeutic use; Sulfonamides - administration & dosage; Sulfonamides - adverse effects; Sulfonamides - pharmacokinetics; United States; United States Food and Drug Administration; VEGF
• ISSN: 1083-7159; 1549-490X
• DOI: 10.1634/theoncologist.2012-0055

Learning Objectives After completing this course, the reader will be able to: Identify the current indications for pazopanib and axitinib. Describe the mechanism of action and the pharmacokinetics of pazopanib and axitinib. Enumerate the clinical benefits of pazopanib and axitinib, and describe the position of these drugs in the treatment paradigm of metastatic renal cell cancer. This article is available for continuing medical education credit at CME.TheOncologist.com Pazopanib and axitinib are both U.S. Food and Drug Administration approved ATP‐competitive inhibitors of the vascular endothelial growth factor receptor. Pazopanib and axitinib have been shown to be effective and tolerable treatment options for patients with metastatic renal cell cancer and therefore have enlarged the armamentarium for this disease. This concise drug review discusses the clinical benefits, clinical use, mechanism of action, bioanalysis, pharmacokinetics, pharmacogenetics, pharmacodynamics, drug resistance, toxicity, and patient instructions and recommendations for supportive care for these two drugs. The clinical benefits, clinical use, mechanism of action, bioanalysis, pharmacokinetics, pharmacogenetics, pharmacodynamics, drug resistance, toxicity, and patient instructions and recommendations for supportive care for pazopanib and axitinib are discussed.